- Phase 3 results of sabizabulin, Veru's ( NASDAQ: VERU ) anti-viral and anti-inflammatory oral drug candidate, have been published in the New England Journal of Medicine .
- Sabizabulin met its primary endpoint. The drug led to a 55.2% relative reduction in deaths in the intent to treat population at day 60.
- The death rate in the placebo arm at that time point was 45.1%, while it was 20.2% in the treatment group.
- Sabizabulin also met secondary endpoints, including reducing days in the ICU, days on ventilation, and days in hospital.
- Veru ( VERU ) filed for Emergency Use Authorization for sabizabulin in June .
For further details see:
Veru phase 3 results of sabizabulin for COVID-19 published in NEJM